With the constant pressure of meeting aggressive process development timelines while continuously improving upstream cell culture yield and productivity, developing the optimal processes from the beginning is crucial. With over 500 adoptions at process and commercial scale across biopharma globally, the XCell® ATF System is a proven technology for intensified cell culture that exponentially boosts productivity, lowers costs, and expands capacity of existing manufacturing facilities in upstream bioprocessing.
In this webinar, learn how the XCell® ATF System with its innovative Alternating Tangential Flow (ATF) technology unlocks up to 10x higher viable cell density (VCD) in half the time and up to 20x increase in productivity compared to traditional fed-batch processes, effectively reducing your cost of goods.
Repligen speaker, Muhammad Shamim will discuss real-world examples of how the system addresses challenges from lab to commercial scales. Register to get an in-depth look at the features and benefits of the recently introduced XCell® LS Controller, designed for integrated process control, seamless scalability, and enhanced productivity.
- Discover how the XCell® ATF System achieves 10x higher MAb titers compared to traditional fed-batch processes.
- Gain insight on how the XCell® LS Controller enhances process control, productivity, scalability, and automation.
- Explore how leading biopharmas leverage XCell® ATF technology to accelerate timelines and expand facility capacity.
- Understand how Repligen’s field applications team can guide your implementation, scale-up, and long-term success with XCell® ATF Systems.
Just fill out the form below to watch the recorded webcast now.